I would take that with a large pinch of salt.
All the article really says is that the first country to approve the product will be the first to get it. That's a statement of the blindingly obvious, not an exclusive arrangement.
Manufacturing is contracted to multiple sites across the globe; there's not one stock which will suddenly be mobilised to one location
eg Catalent in Italy:
https://www.cobrabio.com/news/june-2020/cobra-supply-agreement-astrazeneca-covid19-vaccine
Cobra in Sweden:
Charles River acquires Cobra Biologics, a leading international contract development and manufacturing organization (CDMO) specializing in premium plasmid DNA and viral vector services to support the Advanced Therapy Medicinal Products (ATMP) industry.
www.cobrabio.com
Oxford UK:
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now...
www.oxb.com
India
British drugmaker AstraZeneca has made clear its intent to rapidly scale production of the University of Oxford's COVID-19 vaccine hopeful despite a dearth of clinical data to support its use. | British drugmaker AstraZeneca has made clear its intent to rapidly scale production of the University...
www.fiercepharma.com
etc etc